Esperion Therapeutics Inc to Discuss the Approval and Upcoming Commercial Launch of Nexlizet Conference Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the NEXLIZET FDA approval conference call. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Mr. Alex Schwartz, Head of Investor Relations. Please go ahead, sir.
Thank you, Olivia. Good morning, ladies and gentlemen, and welcome. I'm Alex Schwartz, Head of Investor Relations at Esperion. (Operator Instructions)
Joining me for today's call are Tim Mayleben, President and Chief Executive Officer; Ashley Hall, Chief Development Officer; Mark Glickman, Chief Commercial Officer; Rick Bartram, Chief Financial Officer; and Bill Sasiela, Senior Vice President of Clinical Development.
I'd like to remind callers that the information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |